Andrew Lowy, MD, and Tannishtha Reya, PhD, have been recruited for their expertise in preclinical modeling, clinical trials, and stem cell biology to join a “dream team” of international pancreatic cancer researchers. The three-year, $12-million effort, sponsored by Stand Up To Cancer, Cancer Research UK, and The Lustgarten Foundation, will pursue a three-pronged strategy to better understand and reset so-called “super-enhancers” that may be abnormally active in pancreatic tumors. Super-enhancers are bits of DNA that can cause over-expression of genetic signals, fueling cancer cell growth. Read the full press release
for more information.